Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy.
Department of Urology, University of Rennes, Rennes, France.
Eur Urol. 2019 Jan;75(1):74-84. doi: 10.1016/j.eururo.2018.08.036. Epub 2018 Sep 19.
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally.
To summarise and compare RCC incidence and mortality rates, analyse the magnitude of risk factors, and interpret these epidemiological observations in the context of screening and disease management.
The primary objective of the current review was to retrieve and describe worldwide RCC incidence/mortality rates. Secondly, a narrative literature review about the magnitude of the known risk factors was performed. Finally, data retrieved from the first two steps were elaborated to define the clinical implications for RCC screening.
RCC incidence and mortality significantly differ among individual countries and world regions. Potential RCC risk factors include behavioural and environmental factors, comorbidities, and analgesics. Smoking, obesity, hypertension, and chronic kidney disease represent established risk factors. Other factors have been associated with an increased RCC risk, although selection biases may be present and controversial results have been reported.
Incidence of RCC varies worldwide. Within the several RCC risk factors identified, smoking, obesity, and hypertension are most strongly associated with RCC. In individuals at a higher risk of RCC, the cost effectiveness of a screening programme needs to be assessed on a country-specific level due to geographic heterogeneity in incidence and mortality rates, costs, and management implications. Owing to the low rates of RCC, implementation of accurate biomarkers appears to be mandatory.
The probability of harbouring kidney cancer is higher in developed countries and among smokers, obese individuals, and individuals with hypertension.
尽管在过去 20 年中,肾细胞癌(RCC)的诊断和治疗水平有所提高,但它仍是最致命的泌尿系统恶性肿瘤之一。随着许多疾病常规影像学检查的普及,越来越多的 RCC 患者是偶然发现的。
总结和比较 RCC 的发病率和死亡率,分析危险因素的大小,并结合筛查和疾病管理来解释这些流行病学观察结果。
本次综述的主要目的是检索和描述全球 RCC 的发病率/死亡率。其次,对已知危险因素的大小进行了叙述性文献综述。最后,对前两个步骤中检索到的数据进行了阐述,以确定 RCC 筛查的临床意义。
RCC 的发病率和死亡率在不同国家和世界区域之间存在显著差异。潜在的 RCC 危险因素包括行为和环境因素、合并症和镇痛药。吸烟、肥胖、高血压和慢性肾脏病是已确定的危险因素。其他因素也与 RCC 风险增加相关,尽管可能存在选择偏倚,且已有报道存在争议的结果。
RCC 的发病率在全球范围内存在差异。在已确定的几个 RCC 危险因素中,吸烟、肥胖和高血压与 RCC 相关性最强。对于 RCC 风险较高的个体,由于发病率和死亡率、成本以及管理影响在地理上存在异质性,需要在国家特定层面上评估筛查计划的成本效益。由于 RCC 的发生率较低,因此实施准确的生物标志物似乎是强制性的。
在发达国家以及吸烟者、肥胖者和高血压患者中,患肾癌的可能性更高。